346 related articles for article (PubMed ID: 27799617)
1. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
[TBL] [Abstract][Full Text] [Related]
3. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
[TBL] [Abstract][Full Text] [Related]
4. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
[TBL] [Abstract][Full Text] [Related]
5. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
Brocklebank V; Johnson S; Sheerin TP; Marks SD; Gilbert RD; Tyerman K; Kinoshita M; Awan A; Kaur A; Webb N; Hegde S; Finlay E; Fitzpatrick M; Walsh PR; Wong EKS; Booth C; Kerecuk L; Salama AD; Almond M; Inward C; Goodship TH; Sheerin NS; Marchbank KJ; Kavanagh D
Kidney Int; 2017 Nov; 92(5):1261-1271. PubMed ID: 28750931
[TBL] [Abstract][Full Text] [Related]
6. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
9. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
Bamhraz AA; Rahim KA; Faqeehi HY; Alanazi A
Kidney Blood Press Res; 2020; 45(6):939-954. PubMed ID: 33238263
[TBL] [Abstract][Full Text] [Related]
10. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
Ardissino G; Testa S; Possenti I; Tel F; Paglialonga F; Salardi S; Tedeschi S; Belingheri M; Cugno M
Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
13. Hemolytic Uremic Syndrome in Pregnancy and Postpartum.
Bruel A; Kavanagh D; Noris M; Delmas Y; Wong EKS; Bresin E; Provôt F; Brocklebank V; Mele C; Remuzzi G; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1237-1247. PubMed ID: 28596415
[TBL] [Abstract][Full Text] [Related]
14. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.
Chaturvedi S; Dhaliwal N; Hussain S; Dane K; Upreti H; Braunstein EM; Yuan X; Sperati CJ; Moliterno AR; Brodsky RA
Blood Adv; 2021 Mar; 5(5):1504-1512. PubMed ID: 33683339
[TBL] [Abstract][Full Text] [Related]
16. Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.
Choo SZ; Brown F
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():4-6. PubMed ID: 28176471
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels.
Cugno M; Capone V; Griffini S; Grovetti E; Pintarelli G; Porcaro L; Clementi E; Ardissino G
J Nephrol; 2022 May; 35(4):1205-1211. PubMed ID: 35013983
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up.
Okumi M; Omoto K; Unagami K; Ishida H; Tanabe K
Int Urol Nephrol; 2016 May; 48(5):817-8. PubMed ID: 26865178
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
